Massachusetts worker blames GLP-1 drug for permanent blindness
Ed Gillen, a state highway employee from Dedham, says a GLP-1 medication caused irreversible vision loss, and he has joined a multi-state lawsuit alleging inadequate warnings from the drug’s maker.
Dedham, Mass. – Ed Gillen, a state highway department employee and father of four, reported sudden, complete loss of vision after using a GLP-1 medication for about a year to control his blood-sugar levels. He was diagnosed in May 2025 with non-arteritic anterior ischemic optic neuropathy, a condition that can lead to permanent blindness. Gillen said the symptoms began with a speck in his eye and progressed within two weeks to total loss of sight in both eyes.
"There’s no warning sign at all, there’s no pain; it just comes. It just comes," Gillen said.
He noted that while typical side effects were listed in medical disclosures and advertisements, permanent vision loss was not mentioned. After extensive testing, including MRIs, CT scans and biopsies, a neuro-ophthalmologist concluded the condition was consistent with side effects reported for the GLP-1 drug Ozempic.
The loss of sight forced Gillen to leave his long-time position operating machinery for the highway department. He is now receiving training at the Carroll Center for the Blind to develop adaptive skills for independent living.
Gillen has joined a consolidated lawsuit in federal court in Pennsylvania that accuses Novo Nordisk of failing to adequately warn patients and health-care providers about the risk of severe optic nerve damage and blindness associated with its GLP-1 drugs. Novo Nordisk has responded that internal safety studies have not identified an increased risk of vision loss linked to the medication.